Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon
Autore:
Denton, CP; Bunce, TD; Dorado, MB; Roberts, Z; Wilson, H; Howell, K; Bruckdorfer, KR; Black, CM;
Indirizzi:
Royal Free Hosp, Sch Med, Acad Rheumatol Unit, London NW3 2QG, England Royal Free Hosp London England NW3 2QG tol Unit, London NW3 2QG, England Royal Free Hosp, Sch Med, Dept Biochem & Mol Biol, London NW3 2QG, EnglandRoyal Free Hosp London England NW3 2QG Mol Biol, London NW3 2QG, England
Titolo Testata:
RHEUMATOLOGY
fascicolo: 4, volume: 38, anno: 1999,
pagine: 309 - 315
SICI:
1462-0324(199904)38:4<309:PISARL>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DENSITY-LIPOPROTEIN; SYSTEMIC-SCLEROSIS; SCLERODERMA; DISEASE; INFLAMMATION; PATHOGENESIS; ANGIOPLASTY; PREVENTION; RESTENOSIS; INJURY;
Keywords:
probucol; Raynaud's phenomenon; scleroderma; antioxidant;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Black, CM Royallande Hosp, Sch Med, Acad Rheumatol Unit, Pond St, London NW3 2QG, Eng Royal Free Hosp Pond St London England NW3 2QG don NW3 2QG, Eng
Citazione:
C.P. Denton et al., "Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon", RHEUMATOLOG, 38(4), 1999, pp. 309-315

Abstract

Objective. Reactive oxygen species have been implicated in the pathogenesis of inflammatory and vascular disease. We have undertaken a controlled trial to evaluate probucol, a synthetic antioxidant, as a potential therapy for Raynaud's phenomenon. Methods. The study cohort included patients with systemic sclerosis (SSc; n = 20), primary Raynaud's phenomenon (n = 15) or 'autoimmune Raynaud's' (n= 5). Patients were allocated to receive either probucol (500 mg daily) ornifedipine (20 mg daily) for 12 weeks. Clinical and biochemical variables at baseline were compared with those at completion of treatment. Evaluationincluded assessment of Raynaud's attack frequency and severity by visual analogue scale, measurement of low-density lipoprotein (LDL) oxidation lag time, and plasma concentrations of cholesterol, triglyceride, vitamin E and vitamin C. Results. There was a significant reduction of both the frequency and severity of Raynaud's attacks in the patients who received probucol, but not in the control group. LDL oxidation lag time, reflecting in vitro susceptibility to oxidation, was also increased by probucol therapy and serum cholesterol levels were significantly reduced. Similar changes were observed in bothSSc- and non-SSc-associated Raynaud's cases. Conclusion. These data suggest that probucol may be useful for the symptomatic treatment of Raynaud's phenomenon and also reduces LDL oxidation susceptibility. Since oxidized lipoproteins may mediate vascular damage in SSc, the use of probucol could have additional disease-modifying benefits. Basedupon the results of this pilot study, further evaluation of this novel form of therapy is warranted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 06:48:47